Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells

International Journal of Cancer

Volumn 133, Issue 9, 2013, Pages 2089-2101

  Martinelli, Erika ^a   Troiani, Teresa ^a   D'Aiuto, Elena ^a   Morgillo, Floriana ^a   Vitagliano, Donata ^a   Capasso, Anna ^a   Costantino, Sarah ^a   Ciuffreda, Loreta Pia ^a   Merolla, Francesco ^b   Vecchione, Loredana ^a,c   De Vriendt, Veerle ^c   Tejpar, Sabine ^c   Nappi, Anna ^a   Sforza, Vincenzo ^a   Martini, Giulia ^a   Berrino, Liberato ^a   De Palma, Raffaele ^a   Ciardiello, Fortunato ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

colorectal cancer; combination of molecular targeted therapies; lung cancer; MEK inhibitors

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MSC 2208382; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIMASERTIB; RAF PROTEIN; RAS PROTEIN; REGORAFENIB; SORAFENIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL STRAIN A549; CELL STRAIN COLO205; CELL STRAIN H1299; CELL STRAIN H1975; CELL STRAIN H460; CELL STRAIN HCT15; CELL STRAIN HT29; CELL STRAIN LOVO; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE MODEL; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MICROARRAY ANALYSIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR XENOGRAFT; UPREGULATION;

COLORECTAL CANCER; COMBINATION OF MOLECULAR TARGETED THERAPIES; LUNG CANCER; MEK INHIBITORS;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENYLUREA COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; PYRIDINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84882597506     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28236     Document Type: Article

References (50)

1. Ciardiello F, Tortora G,. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-74.
2. Wong KK, Engelman JA, Cantley LC,. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 2010; 20: 87-90.
3. Ward S, Sotsios Y, Dowden J, Bruce I, Finan P,. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem Biol 2003; 10: 207-13.
4. Yuan TL, Cantley LC,. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008; 27: 5497-510.
5. Castellano E, Downward J,. RAS interaction with PI3K: more than just another effector pathway. Genes Cancer 2011; 2: 261-74.
6. Downward J,. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22.
7. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 17: 1263-84.
8. Shaw RJ, Cantley LC,. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 424-30.
9. Cantley LC,. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-57.
10. Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007; 13: 1576-83.
11. Davies BR, Logie A, McKay JS, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/ pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007; 8: 2209-19.
12. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439: 358-62.
13. Dry JR, Pavey S, Pratilas CA, et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 2010; 70: 2264-73.
14. Mirzoeva OK, Das D, Heiser LM, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009; 69: 565-72.
15. Wee S, Jagani Z, Xiang KX, et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009; 69: 4286-93.
16. Folkes AJ, Ahmadi K, Alderton WK, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl thieno[3,2-d] pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008; 51: 5522-32.
17. Sos ML, Fischer S, Ullrich R, et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci USA 2009; 43: 18351-66.
18. Hoeflich KP, Merchant M, Orr C, et al. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res 2012; 72: 210-19.
19. Smalley KSM, Haass NK, Brafford PA, et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006; 5: 1136-1144.
20. Morgillo F, Cascone T, D'Aiuto E, et al. Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors. Br J Cancer 2011; 105: 382-92.
21. Price S,. Putative allosteric MEK1 and MEK2 inhibitors. Expert Opin Ther Patents 2008; 18: 603-627.
22. Available at: http://www.cancer.gov/clinicaltrials.
23. Kim K, Kong SY, Fulciniti M, et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic antimyeloma activity in vitro and in vivo. Br J Haematol 2010; 149: 537-49.
24. Martinelli E, Troiani T, Morgillo F, et al. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor inhibitors in colorectal and lung cancer cells. Clin Cancer Res 2010; 20: 4990-5001.
25. Nagai H, Sugito N, Matsubara H, et al. CLCP1 interacts with semaphorin 4B and regulates motility of lung cancer cells. Oncogene 2007; 26: 4025-31.
26. Armstrong F, Lamant L, Hieblot C, et al. TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins. Eur J Cancer 2007; 43: 640-46.
27. Emerling BM, Akcakanat A,. Targeting PI3K/mTOR signaling in cancer. Cancer Res 2011; 71: 7351-7359.
28. Maddika S, Kavela S, Rani N, et al. WWP2 is an E3 ubiquitin ligase for PTEN. Nat Cell Biol 2011; 13: 728-33.
29. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 10: 3129-40.
30. Chou T C, Talalay P,. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
31. Tabernero J, Cervantes A, Rivera F, et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol 2010; 28: 1181-89.
32. Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-19.
33. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.
34. Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a metaanalysis of 22 studies. Lung Cancer 2010; 69: 272-78.
35. van Zandwijk N, Mathy A, Boerrigter L, et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Ann Oncol 2007; 18 99-103.
36. Roberts PJ, Stinchcombe TE, Der CJ, et al. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 2010; 31: 4769-77.
37. Friday BB, Adjei AA,. Advances in targeting the Ras/Raf/MEK/Erk mitogenactivated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008; 14: 342-6.
38. Fremin C, Meloche S,. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol 2010; 3: 8-14.
39. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008; 26: 2139-46.
40. Hainsworth JD, Cebotaru CL, Kanarev V, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol 2010; 5: 1630-36.
41. Bennouna J, Lang I, Valladares-Ayerbes M, et al. A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs 2011; 25: 1021-28.
42. Tentler JJ, Nallapareddy S, Tan AC, et al. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Mol Cancer Ther 20109: 3351-62.
43. Garon E, Finn RS, Hosmer W, et al. Identification of common predictive markers of in vitro response to the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther 2010; 9: 1985-94.
44. Troiani T, Vecchione L, Martinelli E, et al. Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase Aactivation in human lung and colorectal cancer cells. Br J Cancer 2012; 106: 1648-59.
45. Yoon J, Koo KH, Choi KY,. MEK1/2 Inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res 2011; 71: 445-53.
46. Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant K-Ras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14: 1351-56.
47. Zhang YJ, Tian XQ, Sun DF, et al. Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer. Cancer Invest 2009; 23: 273-85.
48. Huynh H, Ngo VC, Koong HN, et al. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol 2010; 52: 79-87.
49. Yang S, Ngo VC, Lew GB, et al. AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. Mol Cancer Ther 2009; 8: 2537-2545.
50. Migliardi G, Sassi F, Torti D, et al. Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas. Clin Cancer Res 2012; 9: 2515-25.